Genprex, Inc. 8-K

What Happened
Genprex, Inc. (GNPX) announced on Feb. 10, 2026 (filing date) that IP Australia issued a Notice of Acceptance on Feb. 5, 2026 for the company’s patent application covering the use of REQORSA® gene therapy in combination with PD‑L1 antibodies to treat cancer. The filing also announced the University of Kentucky has been added as a new clinical site for the Acclaim‑3 Phase 1/2 trial, which is evaluating REQORSA plus Genentech’s Tecentriq® (atezolizumab) as maintenance therapy in extensive‑stage small cell lung cancer (ES‑SCLC).

Key Details

• Notice of Acceptance issued by IP Australia on Feb. 5, 2026 for REQORSA + PD‑L1 combination patent application; related claims already granted in the U.S. and Korea.
• Acclaim‑3 is a Phase 1/2 study; Phase 2 expansion plans to enroll ~50 patients; primary endpoint is 18‑week progression‑free survival (PFS) from start of maintenance therapy.
• Genprex expects first 25 patients for the planned interim analysis to complete enrollment in H1 2026, with the interim analysis expected in H2 2026.
• Acclaim‑3 has FDA Fast Track and Orphan Drug designations; Phase 1 dose escalation showed REQORSA was generally well tolerated with no dose‑limiting toxicities.

Why It Matters
A granted Australian patent would give Genprex exclusivity for the REQORSA + PD‑L1 drug combination in Australia, strengthening its intellectual property protection for a therapy being tested in Acclaim‑3 and supporting commercialization and R&D investments. Adding clinical sites like the University of Kentucky aims to speed patient enrollment toward the interim analysis planned for 2026, which could be a near‑term data milestone for investors monitoring the program’s progress. The company also notes it is pursuing patent protection in other key markets (Europe, Canada, Brazil, China, Israel).